Replies to post #202241 on Avid Bioservices Inc (CDMO)

[Carboat]

That all night be true but I'm pphm case, if big pharmaceutical believed the bavi story, they would be all over it. bavi would extend their products life cycle as it used in combo.

[goodplenty100]

Biopharm interesting


Regarding MRI w/contrast, gadolinium-based contrast agents.

To address the need for an MRI contrast agent that demonstrates greater effectiveness and lower toxicity, Dr. Sitharaman developed a novel high-performance graphene-based contrast agent that may replace the gadolinium-based agent which is widely used by physicians today. “A graphene-based contrast agent can allow the same clinical MRI performance at substantially lower dosages,” said Dr. Sitharaman.

Then the below is a must read for those like myself who has and continue to undergo MRI's w/contrast.


http://articles.mercola.com/sites/articles/archive/2014/01/09/gadolinium-mri-contrast-agent.aspx

[biopharm]

SBU Researchers Develop Groundbreaking New Graphene-Based MRI Contrast Agent

June 7, 2012

Must be close on all fronts... including MRI

Convertible MRI contrast: Sensing the delivery and release of anti-glioma nano-drugs

Liang Zhang,
Zhongwei Zhang,
Ralph P. Mason,
Jann N. Sarkaria &
Dawen Zhao


Received
17 November 2014
Accepted
19 March 2015
Published
12 May 2015

Glioblastoma (GBM) is well known for its high resistance to chemotherapy, e.g., temozolomide (TMZ). Building upon the previously established phosphatidylserine (PS)-targeted nanoplatform that has excellent GBM-targeting specificity, we now demonstrate the effectiveness of the targeted nanoformulated ATO for treating TMZ-resistant GBM cells and the ability of the convertible Mn contrast as a surrogate revealing the delivery and release of ATO.

...
..

Affiliations

Radiology, UT Southwestern Medical Center, Dallas, TX
Liang Zhang, Zhongwei Zhang, Ralph P. Mason & Dawen Zhao
Radiation Oncology, Mayo Clinic, Rochester, MN
Jann N. Sarkaria

Contributions

L.Z. and D.Z. designed research; L.Z., Z.Z. and D.Z. performed the research; L.Z., Z.Z. and D.Z. analyzed data; L.Z., R.M., J.S., and D.Z. wrote the paper.
Competing financial interests

The authors declare no competing financial interests.
Corresponding author

Correspondence to:

Dawen Zhao


http://www.nature.com/srep/2015/150512/srep09874/full/srep09874.html